Pharmaxis Ltd
PMXSF
Other OTC0.03
USD
- -
- -
ISIN
AU0000312480
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-16.13
76.60
5Y
-66.84
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gary Jonathan Phillips
- Full Time Employees
- 27
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 20 Rodborough Road Frenchs Forest NSW Australia 2086
- IPO Date
- Sep 22, 2010
- Website
- pharmaxis.com.au
- Similar Companies
- Business
- Syntara Limited, formerly Pharmaxis Ltd, operates as a clinical-stage biopharmaceutical company focused on developing novel small-molecule drugs targeting extracellular matrix dysfunction in fibrosis and inflammation-driven diseases; its lead product candidate, SNT-5505 (formerly PXS-5505), is an oral inhibitor of lysyl oxidases advancing in multinational Phase 2 trials for myelofibrosis, a bone marrow scarring blood cancer, as well as Phase 1c/2 studies for myelodysplastic syndrome; additional pipeline assets include SNT-6302 (formerly PXS-6302) for skin fibrosis and scarring in Phase 1c trials, topical formulations like 9465 for hypertrophic scars, and programs addressing neuroinflammation in Parkinson's disease via collaboration with Parkinson's UK, pulmonary fibrosis, chronic kidney disease, MASH, and cardiac fibrosis.[syntara website] Founded in 1998 and headquartered in Sydney, Australia, the company lists on the ASX under code SNT (formerly PXS; OTC: PMXSF) and conducts operations primarily in Australia with multinational clinical trials across North America, Europe, and other regions targeting haematological malignancies and fibrotic conditions. In late 2023, Syntara completed a major strategic restructuring by selling its mannitol respiratory business, including Bronchitol for cystic fibrosis and Aridol for lung function testing, to Arna Pharma for royalties on sales and manufacturing over eight years, enabling a refocus on clinical drug development as a leaner entity with reduced staff from 70 to 25 and a streamlined board. Recent advancements encompass a A$5.0 million two-tranche placement in 2024 to fund Phase 2 trials amid disputes with Arna Pharma, positive interim Phase 2 safety data for SNT-5505 confirming tolerability in myelofibrosis, initiation of Phase 2 studies in myelodysplastic syndrome with academic partners, FDA feedback paving new trial arms, A$3.6 million R&D tax incentive, cash balance of A$18 million providing an 18-month runway as of Q1 2025, and anticipated milestones including 52-week data readouts, dermatology Phase 1 starts, and potential partnerships in the US$1.9 billion myelofibrosis market amid recent sector acquisitions exceeding US$1.7 billion.
Syntara Limited (PMXSF) Shareholder/Analyst Call Transcript
Syntara Limited (PMXSF) Shareholder/Analyst Call Transcript
Syntara Limited (PMXSF) Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates Transcript
Syntara Limited (PMXSF) Discusses Progress and Future Plans for Skin Scarring Program Transcript
Syntara Limited (PMXSF) Shareholder/Analyst Call Transcript